Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 9—September 2010

CME ACTIVITY

Recurrent Granulibacter bethesdensis Infections and Chronic Granulomatous Disease

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at http://cme.medscape.com/viewpublication/30063; (4) view/print certificate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify infectious organisms in cases of chronic granulomatous disease (CGD).
  • Distinguish the clinical presentation of Granulibacter bethesdensis infection in CGD.
  • Diagnose G. bethesdensis infection in CGD effectively.
  • Plan effective treatment for G. bethesdensis infection in CGD.

Medscape CME Editor

Thomas J. Gryczan, MS, Copyeditor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.

CME AUTHOR

Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

Authors

Disclosures: David E. Greenberg, MD; Adam R. Shoffner, BS; Adrian M. Zelazny, PhD; Michael E. Fenster, MD; Kol A. Zarember, PhD, BSc; Frida Stock, BS; Li Ding, MD; Kimberly R. Marshall-Batty, PhD, MS, BS; Kishore Kanakabandi; Dan E. Sturdevant, PhD; Kimmo Virtaneva; Stephen F. Porcella, PhD; Patrick R. Murray, PhD; Harry L. Malech, MD; and Steven M. Holland, MD, have disclosed no relevant financial relationships. Richard L. Wasserman, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Baxter Healthcare, CSL Behring, Talecris Biotherapeutics; served as a speaker or a member of a speakers bureau for Baxter Healthcare, CSL Behring, Talecris Biotherapeutics; received grants for clinical research from Baxter Healthcare, CSL Behring, Talecris Biotherapeutics, Nabi Biopharmaceuticals. David F. Welch, PhD, has disclosed the following relevant financial relationships: received grants for clinical research from Prodesse (Gen-Probe); owns stock, stock options, or bonds from Cepheid, Luminex Corporation, Merck & Co., Inc., Eli Lilly and Company, Boston Scientific Corporation, Becton, Dickinson and Company.

Article Navigation

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

TOP